Allergy Therapeutics shares grow on clinical news

By
0 mins. to read
Allergy Therapeutics shares grow on clinical news

Shares in commercial biotech company Allergy Therapeutics (LON:AGY) climbed 7.76% to 26.40p (13:20 BST) after the company announced positive top line results from phase II trials for a treatment for glass allergies. All the dosing regimens were safe and well tolerated, with the product showing a significant improvement over placebo.

Get the latest from Master Investor directly in your inbox – Sign-up HERE for FREE

CEO Manuel Llobet said that, “This study represents a major milestone in our path forward to a registered grass allergy product in Europe. Additionally, this brings us closer towards marketing authorisation in the estimated $2bn US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy”.

Take part in our poll

Of the stocks covered by Master Investor in the weekly Small Cap Round Up, which ones do you hold?


The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.

Book your FREE tickets today using code: MIBLOG

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

YOUR FREE INVESTMENT MAG

Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.